$0.02 EPS Expected for STAAR Surgical Company (STAA) This Quarter
Wall Street brokerages expect STAAR Surgical Company (NASDAQ:STAA) to post earnings of $0.02 per share for the current quarter, Zacks reports. Zero analysts have issued estimates for STAAR Surgical’s earnings. STAAR Surgical reported earnings per share of ($0.02) in the same quarter last year, which indicates a positive year over year growth rate of 200%. The business is scheduled to announce its next earnings results after the market closes on Wednesday, November 8th.
On average, analysts expect that STAAR Surgical will report full-year earnings of ($0.03) per share for the current fiscal year, with EPS estimates ranging from ($0.06) to $0.00. For the next financial year, analysts forecast that the company will post earnings of $0.17 per share, with EPS estimates ranging from $0.15 to $0.19. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for STAAR Surgical.
STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.04. The firm had revenue of $21.90 million for the quarter, compared to analyst estimates of $22.15 million. STAAR Surgical had a negative return on equity of 8.69% and a negative net margin of 6.06%. The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.02) earnings per share.
Several research firms have commented on STAA. Canaccord Genuity raised shares of STAAR Surgical from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Monday, September 25th. Zacks Investment Research raised shares of STAAR Surgical from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. TheStreet raised shares of STAAR Surgical from a “d+” rating to a “c” rating in a research report on Tuesday, August 15th. BidaskClub raised shares of STAAR Surgical from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. Finally, Benchmark Co. lifted their target price on shares of STAAR Surgical from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. STAAR Surgical currently has a consensus rating of “Buy” and a consensus price target of $14.00.
Large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. bought a new stake in shares of STAAR Surgical in the 1st quarter worth approximately $111,000. Virtu KCG Holdings LLC bought a new stake in shares of STAAR Surgical in the 2nd quarter worth approximately $118,000. Stephens Inc. AR raised its holdings in shares of STAAR Surgical by 2.6% in the 2nd quarter. Stephens Inc. AR now owns 12,238 shares of the medical instruments supplier’s stock worth $132,000 after purchasing an additional 315 shares during the period. Simplex Trading LLC raised its holdings in shares of STAAR Surgical by 1,798.8% in the 2nd quarter. Simplex Trading LLC now owns 12,779 shares of the medical instruments supplier’s stock worth $138,000 after purchasing an additional 12,106 shares during the period. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in shares of STAAR Surgical in the 2nd quarter worth approximately $214,000. 76.68% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/30/0-02-eps-expected-for-staar-surgical-company-staa-this-quarter.html.
STAAR Surgical (NASDAQ STAA) traded down 2.60% during mid-day trading on Monday, reaching $13.10. The company’s stock had a trading volume of 17,079 shares. The company’s market cap is $538.51 million. The firm has a 50 day moving average price of $12.53 and a 200 day moving average price of $10.89. STAAR Surgical has a 52-week low of $7.45 and a 52-week high of $13.95.
STAAR Surgical Company Profile
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with MarketBeat.com's FREE daily email newsletter.